Maxposure Limited

As of September 30, 2023, Maxposure Limited has 22.74M shares outstanding.

As of September 30, 2023, Maxposure Limited maintains a current ratio of 1.38, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.29, indicating elevated leverage, while an interest coverage ratio of 21.21 demonstrates strong ability to service its debt obligations.

Over the twelve months ended September 30, 2023, Maxposure Limited recorded 21.69M in income tax expense. That works out to an effective tax rate of 36.91, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 58.78M, leaving 37.08M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Maxposure Limited's stock has declined approximately 43.27% over the past 52 weeks. The 50-day moving average sits at 33.62, while the 200-day moving average is 38.22.

Over the twelve months ended September 30, 2023, Maxposure Limited generated 201.61M in revenue and converted that into 37.08M in net income, yielding earnings per share of 1.63. EBITDA reached 61.43M, while operating income came in at 83.44M.

As of September 30, 2023, Maxposure Limited holds 25.60M in cash and equivalents against 46.23M in total debt, resulting in a net debt position of 20.63M. Total book value stands at 347.82M, with working capital of 63.14M providing operational flexibility.

Maxposure Limited produced -2.20M in operating cash flow over the twelve months ended September 30, 2023. After subtracting -8.40M in capital expenditures, free cash flow totaled -10.60M - equivalent to -0.47 per share.

Over the twelve months ended September 30, 2023, Maxposure Limited posted a gross margin of 68.85, reflecting its pricing power and cost economics. The operating margin of 41.38 and net profit margin of 18.39 provide insight into operational efficiency.